PolyPid Ltd. (PYPD)
2.55
0.04 (1.51%)
At close: Apr 10, 2025, 3:56 PM
2.51
-1.59%
After-hours: Apr 10, 2025, 04:12 PM EDT
1.51% (1D)
| Bid | 2.29 |
| Market Cap | 25.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.02M |
| EPS (ttm) | -4.91 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -1.36 |
| Analyst | Buy |
| Ask | 2.76 |
| Volume | 11,617 |
| Avg. Volume (20D) | 17,385 |
| Open | 2.50 |
| Previous Close | 2.51 |
| Day's Range | 2.38 - 2.61 |
| 52-Week Range | 2.30 - 5.09 |
| Beta | 1.28 |
About PYPD
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is head...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 57
Stock Exchange NASDAQ
Ticker Symbol PYPD
Website https://www.polypid.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 311.76% from the latest price.
Stock Forecasts4 months ago
-2.79%
PolyPid shares are trading higher after the compan...
Unlock content with
Pro Subscription
